Summary
We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis. This possible complication has never been previously reported and, since our patient had a history of porphyria, it suggests that bisphosphonates should be administered cautiously in patients with this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Body JJ. Bone metastases and tumor-induced hypercalcemia. Current Opinion in Oncology 1992;4:624–31.
Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int 1993;2:S15–22.
Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994;4:76–83.
Stettler E.R. Central epidemiology and drug safety. Ciba, Basle, Switzerland: personal communication.
Desnick RJ, Anderson KE. Heme biosynthesis and its disorders: the porphyrias and sideroblastic anemias. In: Hematology: Basic principles and practice. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Churchill Livingstone, New York 1991, Chap. 30, 352–357
Sevel D, Burger D. Ocular involvement in cutaneous porphyria. Arch Ophtal 1971;85:580–5.
Wood AJ. Adverse reactions to drugs. In Harrison's principles of internal medicine, 13th edition Editors, K.J. Isselbacher et al., McGraw-Hill Inc 1994, Chap. 67, 405–12.
Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 1994;5:359–63.
Fitton A, Mc. Tavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289–318.
Macarol V, Fraundfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220–24.
Siris ES. Bisphosphoates and iritis. Lancet 1993;341:436–37.
Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 1992;4:1–5.
Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956–62.
Sauty A, Pechertorfer M, Fioroni P, Juillerat L, Leuenberger Ph, Burckhardt P, Thiébaud D. Serum levels of TNF α and IL-6 in patients treated by Pamidronate, Clodronate and BM 21.0955. Bone Miner 1994;25 (Suppl.1):S69.
Oliveri MB, Mautalen C, Mega M, Rossi E. Congenital erythropoietic porphyria — Skeletal manifestations and effects of pamidronate treatment. Bone 1994;15:101–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Des Grottes, J.M., Schrooyen, M., Dumon, J.C. et al. Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol 16, 93–95 (1997). https://doi.org/10.1007/BF02238770
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02238770